Open AccessSignificance of Uracil/Tegafur for Preventing Intravesical Recurrence of Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Author(s) -
Kenichi Harada,
Hideaki Miyake,
Tomoaki Terakawa,
Masato Fujisawa
Publication year - 2012
Publication title -
current urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.476
H-Index - 13
eISSN - 1661-7657
pISSN - 1661-7649
DOI - 10.1159/000338866
Subject(s) - medicine , tegafur , vascular endothelial growth factor , urology , adjuvant , gastroenterology , bladder cancer , angiogenesis , oncology , cancer , vegf receptors
The objective of this study was to assess the role of uracil/tegafur (UFT) and its metabolite γ-butyrolactone (GBL), a potent inhibitor of angiogenesis, in the prevention of intravesical recurrence in patients with non-muscle invasive urothelial carcinoma of the bladder (NMIUCB).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom